Frequencies of HER-2/neu Overexpression Relating to HLA Haplotype in Patients with Gastric Cancer

Overview

Journal Int J Cancer

Specialty Oncology

Date 2002 Feb 22

PMID 11857411

Citations 7

Authors

Koji Kono

Akihiro Takahashi

Hideki Amemiya

Fumiko Ichihara

Hidemitsu Sugai

Hidehiko Iizuka

Hideki Fujii

Yoshiro Matsumoto

Affiliations

Soon will be listed here.

Abstract

We have identified that HER-2/neu-derived peptides are naturally processed as tumor rejection antigens recognized by tumor-specific, HLA-A2-restricted cytotoxic T lymphocytes in gastric cancer. To evaluate candidates for immunotherapy using HER-2/neu-derived, HLA-A2-restricted peptides, we examined the frequency of HLA-A2 relating to HER-2/neu overexpression or the infiltrating grade of tumor-infiltrating lymphocytes (TILs) in Japanese patients with gastric cancer. HER-2/neu-overexpressing tumors detected by immunohistochemistry amounted to 19% of primary gastric cancers and HLA-A2-positive patients with gastric cancer were 31% of primary gastric-cancer cases. Finally, gastric-cancer patients with both HLA-A2-positive and HER-2/neu-overexpressing tumors amounted to 6.6% of these cases. There was no significant difference in the infiltrating grade of TILs between gastric cancers overexpressing HER-2/neu and those that did not. The candidate for HER-2/neu-based immunotherapy with HLA-A2-restricted peptides represent a very limited population of Japanese patients.

Citing Articles

Predictive factors of sensitivity to elisidepsin, a novel Kahalalide F-derived marine compound.

Serova M, de Gramont A, Bieche I, Riveiro M, Galmarini C, Aracil M Mar Drugs. 2013; 11(3):944-59.

PMID: 23519149 PMC: 3705381. DOI: 10.3390/md11030944.

Lapatinib acts on gastric cancer through both antiproliferative function and augmentation of trastuzumab-mediated antibody-dependent cellular cytotoxicity.

Shiraishi K, Mimura K, Izawa S, Inoue A, Shiba S, Maruyama T Gastric Cancer. 2012; 16(4):571-80.

PMID: 23187882 DOI: 10.1007/s10120-012-0219-5.

The atypical histone macroH2A1.2 interacts with HER-2 protein in cancer cells.

Li X, Kuang J, Shen Y, Majer M, Nelson C, Parsawar K J Biol Chem. 2012; 287(27):23171-83.

PMID: 22589551 PMC: 3391143. DOI: 10.1074/jbc.M112.379412.

Combination immunotherapy and active-specific tumor cell vaccination augments anti-cancer immunity in a mouse model of gastric cancer.

van den Engel N, Ruttinger D, Rusan M, Kammerer R, Zimmermann W, Hatz R J Transl Med. 2011; 9:140.

PMID: 21859450 PMC: 3169470. DOI: 10.1186/1479-5876-9-140.

Substitution analog peptide derived from HER-2 can efficiently induce HER-2-specific, HLA-A24 restricted CTLs.

Mimura K, Kono K, Southwood S, Fikes J, Takahashi A, Miyagawa N Cancer Immunol Immunother. 2006; 55(11):1358-66.

PMID: 16435129 PMC: 11030792. DOI: 10.1007/s00262-006-0123-0.